Neurocrine Biosciences, Inc. Common Stock Earnings Dividend

Neurocrine Biosciences, Inc. Common Stock’s revenue jumped 39.49% since last year same period to $959Mn in the Q2 2026. On a quarterly growth basis, Neurocrine Biosciences, Inc. Common Stock has generated 17.74% jump in its revenue since last 3-months.

Neurocrine Biosciences, Inc. Common Stock’s net profit jumped 34.33% since last year same period to $144.4Mn in the Q2 2026. On a quarterly growth basis, Neurocrine Biosciences, Inc. Common Stock has generated -27.03% fall in its net profits since last 3-months.

Neurocrine Biosciences, Inc. Common Stock’s net profit margin fell -3.7% since last year same period to 15.06% in the Q2 2026. On a quarterly growth basis, Neurocrine Biosciences, Inc. Common Stock has generated -38.03% fall in its net profit margins since last 3-months.

Neurocrine Biosciences, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 1.88 - a 10.59% jump from last quarter’s estimates.

Neurocrine Biosciences, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 1.88.

Neurocrine Biosciences, Inc. Common Stock’s earning per share (EPS) jumped 43.03% since last year same period to 2.36 in the Q2 2026. This indicates that the Neurocrine Biosciences, Inc. Common Stock has generated 43.03% annual rate of jump in its earning per share (EPS) in the last 4 quarters.